IL245045B - Selective pyy compounds and their uses - Google Patents

Selective pyy compounds and their uses

Info

Publication number
IL245045B
IL245045B IL245045A IL24504516A IL245045B IL 245045 B IL245045 B IL 245045B IL 245045 A IL245045 A IL 245045A IL 24504516 A IL24504516 A IL 24504516A IL 245045 B IL245045 B IL 245045B
Authority
IL
Israel
Prior art keywords
pyy compounds
selective
selective pyy
compounds
pyy
Prior art date
Application number
IL245045A
Other languages
English (en)
Hebrew (he)
Other versions
IL245045A0 (en
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL245045A0 publication Critical patent/IL245045A0/en
Publication of IL245045B publication Critical patent/IL245045B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
IL245045A 2013-11-15 2016-04-11 Selective pyy compounds and their uses IL245045B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13193082 2013-11-15
US201361906020P 2013-11-19 2013-11-19
EP14176725 2014-07-11
PCT/EP2014/074476 WO2015071355A1 (en) 2013-11-15 2014-11-13 Selective pyy compounds and uses thereof

Publications (2)

Publication Number Publication Date
IL245045A0 IL245045A0 (en) 2016-05-31
IL245045B true IL245045B (en) 2019-09-26

Family

ID=53056816

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245045A IL245045B (en) 2013-11-15 2016-04-11 Selective pyy compounds and their uses

Country Status (15)

Country Link
US (2) US10246497B2 (cg-RX-API-DMAC7.html)
EP (1) EP3068421B1 (cg-RX-API-DMAC7.html)
JP (1) JP6602760B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160075819A (cg-RX-API-DMAC7.html)
CN (1) CN105722526B (cg-RX-API-DMAC7.html)
AU (1) AU2014350197B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016010383A2 (cg-RX-API-DMAC7.html)
CA (1) CA2929672A1 (cg-RX-API-DMAC7.html)
IL (1) IL245045B (cg-RX-API-DMAC7.html)
MX (1) MX369818B (cg-RX-API-DMAC7.html)
PL (1) PL3068421T3 (cg-RX-API-DMAC7.html)
RS (1) RS59026B1 (cg-RX-API-DMAC7.html)
SI (1) SI3068421T1 (cg-RX-API-DMAC7.html)
TW (1) TWI661835B (cg-RX-API-DMAC7.html)
WO (1) WO2015071355A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036066T2 (hu) 2010-12-16 2018-06-28 Novo Nordisk As GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
MY172578A (en) 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds
UY35548A (es) * 2013-05-02 2014-11-28 Glaxosmithkline Ip No 2 Ltd Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
RS59026B1 (sr) 2013-11-15 2019-08-30 Novo Nordisk As Selektivna pyy jedinjenja i njihova upotreba
CA2988500A1 (en) * 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof
AU2017256774B2 (en) 2016-04-28 2024-07-11 Novo Nordisk A/S Semaglutide in cardiovascular conditions
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
WO2019106193A1 (en) 2017-12-01 2019-06-06 University Of Copenhagen Peptide hormone with one or more o-glycans
AU2019206391A1 (en) * 2018-01-09 2020-07-16 Gila Therapeutics, Inc Compositions and methods for treating metabolic diseases
RS64643B1 (sr) 2018-02-02 2023-10-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i lubrikant
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
TW202535916A (zh) 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
JP2022543826A (ja) * 2019-08-07 2022-10-14 ノヴォ ノルディスク アー／エス Ｐｙｙ化合物とｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
CA3156452A1 (en) * 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
CA3185637A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
KR20230106616A (ko) * 2020-11-09 2023-07-13 엠바크 바이오테크 에이피에스 타키키닌 수용체 매개 장애의 치료에 있어서의 화합물 및 이의 용도
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
WO2025128624A2 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent
WO2025128626A1 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a modified lysine residue

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157766A1 (en) 1993-03-29 1994-10-13 Ambikaipakan Balasubramaniam Analogs of peptide yy and uses thereof
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
JP2002517483A (ja) 1998-06-08 2002-06-18 シェーリング コーポレイション 神経ペプチドｙ５レセプターアンタゴニスト
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
RU2275207C2 (ru) 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
BR0212985A (pt) 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
CN102174115B (zh) 2004-02-11 2014-05-14 安米林药品有限责任公司 具有可选择特性的杂合多肽
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
CN1953763A (zh) 2004-03-17 2007-04-25 7Tm制药联合股份有限公司 用于治疗性干预的y4选择性受体激动剂
JP2007531713A (ja) 2004-03-17 2007-11-08 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ２選択性レセプターアゴニスト
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
CA2560166A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
AU2005261740A1 (en) 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2007008778A2 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
CN101222942A (zh) 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
EA200800874A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия
CN101268096A (zh) 2005-09-21 2008-09-17 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
WO2007065808A2 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
WO2007068718A1 (en) 2005-12-14 2007-06-21 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
JP5412273B2 (ja) 2006-03-21 2014-02-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー ペプチド−ぺプチダーゼ阻害剤及びその使用
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
EP2106405A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
BRPI0814629A2 (pt) 2007-07-09 2015-01-27 Imp Innovations Ltd Compostos e seus efeitos sobre o comportamento alimentar
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100210559A1 (en) 2007-09-11 2010-08-19 Mondobiotech Laboratories Ag Trap-14 as a therapeutic agent
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
AU2009248041B2 (en) 2008-05-16 2013-10-03 Novo Nordisk A/S Long-acting Y2 and/or Y4 receptor agonists
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
BRPI0921230A2 (pt) 2008-11-05 2018-10-30 Hoffmann La Roche agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
CA2752608A1 (en) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide y receptor binding compound
US20130040877A1 (en) 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
JP2013507414A (ja) 2009-10-13 2013-03-04 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
CN102905722A (zh) 2009-11-13 2013-01-30 诺沃—诺迪斯克有限公司 长效y2受体激动剂
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
MX366325B (es) * 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
WO2013178490A1 (en) 2012-05-29 2013-12-05 Novo Nordisk A/S Pancreatic polypeptide compounds and use
UY35548A (es) 2013-05-02 2014-11-28 Glaxosmithkline Ip No 2 Ltd Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
RS59026B1 (sr) 2013-11-15 2019-08-30 Novo Nordisk As Selektivna pyy jedinjenja i njihova upotreba
CA2988500A1 (en) * 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof

Also Published As

Publication number Publication date
US10246497B2 (en) 2019-04-02
EP3068421A1 (en) 2016-09-21
CA2929672A1 (en) 2015-05-21
US20160289283A1 (en) 2016-10-06
AU2014350197B2 (en) 2018-10-04
US20150152150A1 (en) 2015-06-04
US9085637B2 (en) 2015-07-21
WO2015071355A1 (en) 2015-05-21
PL3068421T3 (pl) 2019-11-29
CN105722526A (zh) 2016-06-29
JP6602760B2 (ja) 2019-11-06
JP2017505284A (ja) 2017-02-16
SI3068421T1 (sl) 2019-08-30
TW201605467A (zh) 2016-02-16
CN105722526B (zh) 2020-12-08
MX2016006053A (es) 2016-08-17
TWI661835B (zh) 2019-06-11
KR20160075819A (ko) 2016-06-29
RS59026B1 (sr) 2019-08-30
EP3068421B1 (en) 2019-04-17
AU2014350197A1 (en) 2016-05-05
IL245045A0 (en) 2016-05-31
MX369818B (es) 2019-11-22
BR112016010383A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
IL274355B (en) Aza-pyridone compounds and their uses
IL276113B (en) Electronic smoking part and electronic smoking device
IL245045A0 (en) Selective pyy compounds and their uses
IL240275A0 (en) Selective antisense compounds and their uses
ZA201603549B (en) New pesticidal compounds and uses
GB201323008D0 (en) Compounds and uses thereof
GB201317802D0 (en) SmartHaler patent application
IL240248A0 (en) Met-binding substances and their uses
GB201300707D0 (en) Compounds and processes
IL244214B (en) Thienopiperidine derivative and its use
GB201307233D0 (en) Compounds and uses thereof
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201309180D0 (en) Compounds and Their Uses
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
GB201300001D0 (en) Envirep - environment replicater
PT3068421T (pt) Compostos de pyy eletivo e usos dos mesmos
AU5373P (en) Sungelobu Angelonia angustifolia
AU5375P (en) Sungeloho Angelonia angustifolia
AU5374P (en) Sungelodepi Angelonia angustifolia
GB201309248D0 (en) Compounds and combinations
GB201323005D0 (en) Compounds and uses thereof
GB201320161D0 (en) Compounds and their uses
GB201307201D0 (en) New compounds and uses

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees